Hormonal
GLP-1 receptor agonists (specifically liraglutide, semaglutide, and dulaglutide) significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk, independent of baseline BMI.
If you have Type 2 Diabetes and high heart risk, GLP-1 medications like liraglutide, semaglutide, or dulaglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. These benefits exist even if your weight loss isn't massive. Discuss these options with your doctor, especially if you have existing heart disease.
There was a 13% reduction in the primary composite outcome (death from CV causes, non-fatal myocardial infarction, or non-fatal stroke) in the liraglutide group compared to placebo (HR 0.87, 95% CI 0.78 – 0.97, p<0.001)... There was a 26% reduction in the primary outcome... in the semaglutide group compared to placebo (HR 0.74, 95% CI 0.58 – 0.95, p <0.001)... there was a 12% reduction in the primary outcome in the dulaglutide group compared to the placebo (HR 0.88, 95% CI 0.79 – 0.99, p¼0.026).
Why this rating
Based on multiple large-scale, long-duration Randomized Controlled Trials (RCTs) with clear statistical significance.
Source
A review of the evidence on cardiovascular outcomes from obesity treatment
Roshaida Abdul Wahab et al. · Obesity Pillars · 2023
DOI 10.1016/j.obpill.2023.100071
More from this paper
- SGLT2 inhibitors (specifically empagliflozin and canagliflozin) reduce major adverse cardiovascular events (MACE) in patients with Type 2 Diabetes, with empagliflozin also reducing heart failure hospitalizations.Strong
- Bariatric surgery significantly reduces all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE) compared to medical therapy in patients with severe obesity and Type 2 Diabetes.Good
- Intensive lifestyle intervention in patients with Type 2 Diabetes and obesity does not significantly reduce major cardiovascular events compared to standard care, although weight loss of 10% or more is associated with a lower risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →